Oxcarbazepine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Oxcarbazepine: From Focal Epilepsy to Visual Epilepsy
One-Sentence Summary
Oxcarbazepine is a second-generation antiepileptic drug (AED), globally established for the treatment of partial-onset (focal) epilepsy, though it is not currently licensed in this jurisdiction. The TxGNN model predicts it may be effective for Visual Epilepsy (a photosensitive/reflex seizure subtype), with 1 clinical trial and 19 publications currently available as supporting context — though none are specific to this seizure subtype.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not licensed in this jurisdiction (drug status: not marketed); globally established indication is focal (partial-onset) epilepsy, per literature evidence |
| Predicted New Indication | Visual Epilepsy |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L3 |
| US Market Status | ✗ Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, oxcarbazepine belongs to the second-generation antiepileptic drug (AED) class — it is the keto-analogue of carbamazepine. Its efficacy in partial-onset (focal) epilepsy has been proven over decades of clinical use, and mechanistically it may be applicable to visual epilepsy.
Oxcarbazepine’s active metabolite (10-monohydroxy derivative, MHD) acts as a voltage-dependent sodium channel blocker. This core antiseizure mechanism already covers essentially all focal seizure types. Visual (photosensitive/pattern-induced) epilepsy is considered a reflex seizure subtype within the broader focal/generalized seizure spectrum, so the mechanism can plausibly be extrapolated to this population.
It should be noted, however, that this represents largely an extension of an already-established indication rather than a genuinely novel repurposing target. As the evidence pack’s own rationale states, the TxGNN model appears to be recovering a known drug-class relationship (AEDs treat reflex/visually-induced seizures as a matter of course) rather than surfacing an unexpected new use.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00855738 | Phase 4 | Completed | 111 | Observational study assessing new AEDs (gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine, topiramate) as first-choice bitherapy in focal epilepsy. Relevance grade B — general focal-epilepsy population evidence, not specific to visual/photosensitive epilepsy. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32129501 | 2020 | Cochrane Systematic Review | Cochrane Database Syst Rev | Oxcarbazepine as add-on therapy for drug-resistant focal epilepsy. |
| 35429132 | 2022 | RCT | CNS Neurosci Ther | Multicenter, open-label, randomized study comparing oxcarbazepine vs. levetiracetam monotherapy in newly diagnosed focal epilepsy (China). |
| 35380580 | 2022 | Review | JAMA | Overview of antiseizure medications for adults with epilepsy. |
| 33334546 | 2020 | Review | Seizure | Current role of carbamazepine and oxcarbazepine in epilepsy management. |
| 10530693 | 1999 | Review | Epilepsia | Oxcarbazepine as first-line therapy for partial and generalized tonic-clonic seizures. |
| 37092337 | 2023 | Review | Pharmacogenomics | Pharmacogenomic variability in oxcarbazepine efficacy/safety across populations. |
| 39899099 | 2025 | Review | Continuum (Minneap Minn) | Update on antiseizure medications, 2025. |
| 26844734 | 2016 | Review | Continuum (Minneap Minn) | Overview of antiepileptic drugs including oxcarbazepine’s spectrum of use. |
| 1379159 | 1992 | Review | Drugs | Pharmacology and therapeutic potential of oxcarbazepine in epilepsy, trigeminal neuralgia, and affective disorders. |
| 11772334 | 2002 | Review | Expert Opin Pharmacother | Oxcarbazepine efficacy as adjunctive and monotherapy for partial-onset seizures. |
US Market Information
The drug is currently not marketed in this jurisdiction (market_status: 未上市, total_licenses: 0), so no license/NDA records are available to display.
Safety Considerations
Please refer to the package insert for safety information.
(Note: local label warnings, contraindications, and drug interaction data are currently a data gap — see Conclusion below.)
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanism of sodium-channel blockade is broadly applicable to reflex/focal seizure subtypes including visual epilepsy, and this is supported by one Phase 4 observational trial and multiple reviews on oxcarbazepine’s established role in focal epilepsy — but no evidence specifically addresses visual/photosensitive epilepsy, and this candidate largely reflects a known indication extension rather than a novel repurposing signal.
To proceed, the following is needed:
- Local package insert warnings/contraindications (currently a Blocking data gap — required before safety pre-screening, S1)
- Detailed mechanism of action (MOA) documentation from DrugBank
- Visual-epilepsy-specific case series or trial evidence to confirm applicability beyond general focal-epilepsy population data
- Regulatory pathway assessment, since the drug is not currently marketed/licensed in this jurisdiction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.